RGNX Quote, Financials, Valuation and Earnings

Insmed has a net margin of -241.28% compared to Regenxbio's net margin of -225.53%. Regenxbio's return on equity of -70.45% beat Insmed's return on equity of -41989.34%.

Regenxbio has a consensus price target of $32.50, signalling upside risk potential of 447.14%. On the other hand Insmed has an analysts' consensus of $97.24 which suggests that it could grow by 33.85%. Given that Regenxbio has higher upside potential than Insmed, analysts believe Regenxbio is more attractive than Insmed.

Regenxbio has a beta of 1.263, which suggesting that the stock is 26.294% more volatile than S&P 500. In comparison Insmed has a beta of 1.072, suggesting its more volatile than the S&P 500 by 7.18%.

Regenxbio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regenxbio pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

Regenxbio quarterly revenues are $21.2M, which are smaller than Insmed quarterly revenues of $104.4M. Regenxbio's net income of -$51.2M is higher than Insmed's net income of -$235.5M. Notably, Regenxbio's price-to-earnings ratio is -- while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regenxbio is 3.53x versus 32.76x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -241.28% compared to Regenxbio's net margin of 24.22%. Regenxbio's return on equity of -70.45% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Regenxbio has a consensus price target of $32.50, signalling upside risk potential of 447.14%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $890.34 which suggests that it could grow by 58.1%. Given that Regenxbio has higher upside potential than Regeneron Pharmaceuticals, analysts believe Regenxbio is more attractive than Regeneron Pharmaceuticals.

Regenxbio has a beta of 1.263, which suggesting that the stock is 26.294% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.337%.

Regenxbio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.16% to investors and pays a quarterly dividend of $0.88 per share. Regenxbio pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Regenxbio quarterly revenues are $21.2M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Regenxbio's net income of -$51.2M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Regenxbio's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 14.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regenxbio is 3.53x versus 4.56x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -241.28% compared to Regenxbio's net margin of 24.16%. Regenxbio's return on equity of -70.45% beat Sarepta Therapeutics's return on equity of 20.83%.

Regenxbio has a consensus price target of $32.50, signalling upside risk potential of 447.14%. On the other hand Sarepta Therapeutics has an analysts' consensus of $151.08 which suggests that it could grow by 186.45%. Given that Regenxbio has higher upside potential than Sarepta Therapeutics, analysts believe Regenxbio is more attractive than Sarepta Therapeutics.

Regenxbio has a beta of 1.263, which suggesting that the stock is 26.294% more volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.930, suggesting its less volatile than the S&P 500 by 6.993%.

Regenxbio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regenxbio pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Regenxbio quarterly revenues are $21.2M, which are smaller than Sarepta Therapeutics quarterly revenues of $658.4M. Regenxbio's net income of -$51.2M is lower than Sarepta Therapeutics's net income of $159M. Notably, Regenxbio's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 23.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regenxbio is 3.53x versus 3.15x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -241.28% compared to Regenxbio's net margin of 31.35%. Regenxbio's return on equity of -70.45% beat Vertex Pharmaceuticals's return on equity of -3.23%.

Regenxbio has a consensus price target of $32.50, signalling upside risk potential of 447.14%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $498.43 which suggests that it could grow by 1.91%. Given that Regenxbio has higher upside potential than Vertex Pharmaceuticals, analysts believe Regenxbio is more attractive than Vertex Pharmaceuticals.

Regenxbio has a beta of 1.263, which suggesting that the stock is 26.294% more volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.617%.

Regenxbio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regenxbio pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Regenxbio quarterly revenues are $21.2M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. Regenxbio's net income of -$51.2M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, Regenxbio's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regenxbio is 3.53x versus 11.51x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.